Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$69.74
-5.97%
Alpha Vantage · 11/6/2026
Adjusted daily closes · 252 observations · as of Nov 6, 2026
1 month
+8.1%
3 months
+4.8%
6 months
+24.6%
1 year
+88.0%
Year to date
+69.5%
52-week range
$31.80 – $76.01
Latest reported period: Sep 30, 2026
Market cap
$34.53B
P/E
23.6
P/B
1.6
P/S
0.2
Revenue
$203.9B
Net income
$1.46B
Diluted EPS
2.92
Gross margin
7.80%
Net margin
0.70%
Return on equity
6.80%
Total debt
$15.54B
Cash
$20.7B
Free cash flow
$3.94B
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Sep 30, 2026 | $50.65B | -$71M | 6.40% | -0.10% | -$3.86B |
| Jun 30, 2026 | $53.58B | $1.09B | 8.60% | 2.00% | $3.42B |
| Mar 31, 2026 | $49.94B | $1.54B | 11.10% | 3.10% | $4.17B |
| Dec 31, 2025 | $49.73B | -$1.1B | 5.00% | -2.20% | $224M |
| Sep 30, 2025 | $49.69B | -$6.63B | 6.50% | -13.30% | $1.15B |
| Jun 30, 2025 | $48.74B | -$253M | 6.00% | -0.50% | $1.58B |
| Mar 31, 2025 | $46.62B | $1.31B | 11.20% | 2.80% | $1.38B |
| Dec 31, 2024 | $40.81B | $283M | 9.10% | 0.70% | -$741M |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Centene (NYSE: CNC) has significantly outperformed the market over the last 15 years, achieving an average annual return of 15.29%. An initial investment of $100 in Centene stock 15 years ago would now be worth $844.42, demonstrating the powerful effect of compounded returns over time. The company currently holds a market capitalization of $33.41 billion.
Original sourceCVS Health is suing the federal government to challenge its 2027 Medicare Advantage star ratings, aiming to avert a potential revenue loss exceeding $2 billion due to declining quality scores. The lawsuit argues that the CMS used illegal methodology and improperly adopted measures to calculate the ratings. CVS joins at least four other insurers in similar lawsuits, all citing a previous ruling that found CMS measures for 2026 scores to be illegal.
Original sourceAfter a buoyant third quarter, Centene now thinks its Medicare business will break even one year ahead of schedule. Staffing cuts saddled the insurer with severance spending, but should help margins in 2027.
Original sourceThe St. Louis-based insurer is adding onto a growing pile of lawsuits from insurers trying to get their quality scores recalculated — and nab hundreds of millions of dollars in extra payments as a result.
Original source